Pharmaceutical care for a child with severe pneumonia infected by MP combined with hMPV and SP

doi:10.3760/cma.j.issn.1007-1245.2024.10.027

Abstract

Abstract:

The clinical pharmacists participated in the pharmaceutical care of a child with severe pneumonia infected by Myocoplasima pneumonia (MP) combined with human metapneumovirus (hMPV) and streptococcus pneumonia (SP) throughout the entire process. In cases where the physicians ignored MP, used off-label drug, and violated traditional theory of drug combination with the complex disease, the clinical pharmacists timely provided safe and effective analyses and suggestions of the treatment plan, monitored the efficacies and adverse reactions, and provided medication guidance through searching for information and in-depth analyses of the disease situation. It ensured the safety and effectiveness of medication for the child effectively, provided the effective pharmaceutical services for clinical practice, and provided reference for drug treatment and care of such patients at the same time.

Key words:

Mycoplasma pneumonia, Human metapneumovirus, Streptococcus pneumonia, Severe pneumonia, Child, Pharmaceutical care

摘要：

临床药师全程参与1例肺炎支原体（MP）合并偏肺病毒（hMPV）和肺炎链球菌（SP）感染的重症肺炎患儿药学监护，在患儿病情复杂、医师忽略MP感染、超说明书用药和违反传统理论联合用药的情况下，查阅资料，结合病情深入剖析，及时提供安全有效的治疗方案分析和建议，监测疗效和不良反应，进行用药指导；较好地保障了患儿用药的安全性和有效性，提供了有效的药学服务，同时为此类患儿的药物治疗和监护提供参考。

关键词:

肺炎支原体, 偏肺病毒, 肺炎链球菌, 重症肺炎, 患儿, 药学监护

Duan Xiaoju, Bi Wenchao, Hou Jingjing, Wang Yan, Gu Yu, Liu Xianyong, Zheng Junqing.

Pharmaceutical care for a child with severe pneumonia infected by MP combined with hMPV and SP [J]. International Medicine and Health Guidance News, 2024, 30(10): 1716-1719.

段小菊毕文超侯静静王岩谷雨刘宪勇郑俊青.

MP合并hMPV和SP感染的重症肺炎患儿1例药学监护 [J]. 国际医药卫生导报, 2024, 30(10): 1716-1719.

References

[1] 中华人民共和国国家健康委员会,国家中医药局.儿童社区获得性肺炎诊疗规范(2019年版)[J].中华临床感染病杂志,2019,12(1):6-13. DOI:10.3760/cma.j.issn.1674-2397. 2019.01.002.
[2] 国家呼吸系统疾病临床医学研究中心,国家儿童医学中心,中华医学会儿科学分会呼吸学组,等.中国儿童肺炎链球菌性疾病诊断、治疗和预防专家共识[J].中华实用儿科临床杂志,2020,35(7):485-505. DOI:10.3760/cma.j.cn101070- 20200306-00329.
[3] 中华人民共和国国家卫生健康委员会.儿童肺炎支原体肺炎诊疗指南(2023年版)[J].中国合理用药探索,2023,20(3):16-24. DOI:10.3969/j.issn.2096-3327.2023.03.003.
[4] 中国医药教育协会感染疾病专业委员会.抗菌药物药代动力学/药效学理论临床应用专家共识[J].中华结核和呼吸杂志,2018,41(6):409-446. DOI:10.3760/cma.j.issn.1001- 0939.2018.06.004.
[5] Oishi T, Yoshioka D, Nakano T, et al. Recent trend of antimicrobial susceptibility among mycoplasma pneumonia isolated from Japanese children[J]. Microorganisms, 2022, 10(12):2428. DOI: 10.3390/microorganisms10122428.
[6] Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues[J]. J Antimicrob Chemother, 1990, 25 Suppl A:73-82. DOI: 10.1093/jac/25.suppl_a.73.
[7] Wang Z, Chu C, Ding Y, et al. Clinical significance of serum microRNA-146a and inflammatory factors in children with mycoplasma pneumoniae pneumonia after azithromycin treatment[J]. J Pediatr (Rio J), 2024, 100(1):108-115. DOI: 10.1016/j.jped.2023.06.004.
[8] Zhao F, Li J, Liu J, et al. Antimicrobial susceptibility and molecular characteristics of mycoplasma pneumonia isolates across different regions of China[J]. Antimicrob Resist Infect Control, 2019, 8:143. DOI: 10.1186/s13756- 019-0576-5.
[9] 李少丽,孙红妹.肺炎支原体大环内酯类抗生素全球耐药现状和耐药机制研究进展[J].中华微生物学和免疫学杂志,2018,38(5):395-400. DOI:10.3760/cma.j.issn.0254-5101. 2018.05.011.
[10] Bébéar C, Pereyre S, Peuchant O. Mycoplasma pneumoniae: susceptibility and resistance to antibiotics[J]. Future Microbiol, 2011, 6(4):423-431. DOI: 10.2217/fmb.11.18.
[11] 马晓林,丁臻博,黄永坤.儿童肺炎支原体对大环内酯类抗生素耐药现状及机制研究进展[J].国际药学研究杂志,2020,47(10):804-808. DOI:10.13220/j.cnki.jipr.2020.10.007.
[12] 贾金荣,陈步信,庾伟君,等.耐药基因23Sr RNA的A2063G基因位点突变肺炎支原体肺炎62例临床分析[J].国际医药卫生导报,2023,29(23):3439-3442. DOI:10.3760/cma.j.issn.1007-1245.2023.23.026.
[13] 孟晨,吴福玲,宁君,等.山东省肺炎支原体肺炎住院患儿横断面研究[J].中华实用儿科临床杂志,2022,37(16):1245-1251. DOI:10.3760/cma.j.cn101070-20220107- 00027.
[14] Tsai TA, Tsai CK, Kuo KC, et al. Rational stepwise approach for mycoplasma pneumoniae pneumonia in children[J]. J Microbiol Immunol Infect, 2021, 54(4):557-565. DOI: 10.1016/j.jmii.2020.10.002.
[15] 戴单单,朱素燕,徐萍,等.α干扰素雾化吸入的研究进展[J].中国临床药学杂志,2020,29(4):316-318.DOI:10.19577/j.1007-4406.2020.04.022.
[16] Peiffer-Smadja N, Yazdanpanah Y. Nebulised interferon beta-1a for patients with COVID-19[J]. Lancet Respir Med, 2021, 9(2):122-123. DOI: 10.1016/S2213-2600(20)30523-3.
[17] 申昆玲,尚云晓,张国成,等.α干扰素在儿科临床合理应用专家共识[J].中华实用儿科临床杂志,2018,33(17):1301-1308. DOI:10.3760/cma.j.issn.2095- 428X.2018.17.006.
[18] 国家呼吸系统疾病临床医学研究中心,中华医学会儿科学分会呼吸学组,中国医师协会呼吸医师分会儿科呼吸工作委员会,等.儿童呼吸道合胞病毒感染诊断、治疗和预防专家共识[J].中华实用儿科临床杂志,2020,35(4):241-250.DOI:10.3760/cma.j.cn101070-20200225-00243.
[19] 中华人民共和国国家卫生健康委员会.新型冠状病毒肺炎诊疗方案(试行第八版)[J].中华临床感染病杂志,2020,13(5):321-328. DOI:10.3760/cma.j.issn.1674-2397. 2020.05.001.
[20] 湖南省卫生健康委员会.湖南省儿童新冠肺炎临床诊断与治疗专家共识(试行第一版).湘卫医政医管处便函〔2020〕34号.
[21] 人偏肺病毒感染诊疗方案(2023年版)[J].中国感染控制杂志,2023,22(7):869-870. DOI:10.12138/j.issn.1671-9638. 20232305.
[22] 中华医学会临床药学分会«雾化吸入疗法合理用药专家共识» 编写组.雾化吸入疗法合理用药专家共识(2019年版)[J].医药导报,2019,38(2):135-146. DOI:10.3870/j.issn.1004-0781.2019.02.001.
[23] 洪建国,陈强,陈志敏,等.儿童常见呼吸道疾病雾化吸入治疗专家共识[J].中国实用儿科杂志,2012,27(4):265-269.
[24] CHINET中国细菌耐药监测网.CHINET 2023年上半年细菌耐药监测结果[DB/OL].http://www.chinets.com/Document/Index?pageIndex=0#.
[25] 阿奇霉素干混悬剂说明书.2022年版.辉瑞制药有限公司.
[26] 注射用哌拉西林钠他唑巴坦钠说明书.2020年版.Wyeth Lederle S.R.L.
[27] Ambroggio L, Taylor JA, Tabb LP, et al. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia[J]. J Pediatr, 2012, 161(6):1097-1103. DOI: 10.1016/j.jpeds.2012.06.067.
[28] Zeng L, Xu P, Choonara I, et al. Safety of azithromycin in pediatrics: a systematic review and meta-analysis[J]. Eur J Clin Pharmacol, 2020, 76(12):1709-1721. DOI: 10.1007/s00228-020-02956-3.
[29] 赵紫楠,刘蕾,李可欣,等.α-干扰素雾化吸入的快速卫生技术评估及其在新型冠状病毒肺炎中应用的可能与价值[J].临床药物治疗杂志,2020,18(3):38-41. DOI:10.3969/j.issn.1672-3384.2020.03.008.
[30] 王兵,程婷,卢晨,等.重组人干扰素α2b与儿童雾化吸入药物的配伍研究[J/CD].中华妇幼临床医学杂志(电子版),2017,13(4):474-481. DOI:10.3877/cma.j.issn.1673-5250. 2017.04.019.
[31] 吴婷婷,宋晓波,张昱,等.多种厌氧菌感染致肺脓肿1例的药物治疗方案分析[J].国际医药卫生导报,2022,28(18):2579-2582. DOI:10.3760/cma.j.issn.1007-1245.2022. 18.014.